HCW Biologics Inc. (NASDAQ:HCWB) stock is falling on Monday. Retail investors are taking profits following a massive 262% surge during the previous trading session.



Despite the pullback, the stock remained sharply higher overall.



Nasdaq futures are down 0.37% while S&amp;P 500 futures have shed 0.43%.



<h2>Quarterly Financials and Pipeline Milestones</h2>



On Friday, reports highlighted that HCWB surged after reporting stronger quarterly results. The company highlighted progress across its autoimmune pipeline. Sentiment improved after the biotech company advanced a licensing deal and reaffirmed clinical milestones.



For the first quarter, HCW reported earnings per share of 37 cents. Quarterly sales reached $6.54 million, up from $5,065 a year ago.



The company completed an exclusive worldwide licensing agreement with Trimmune for the in vivo rights for HCW11-006.



HCW expects preliminary clinical data readouts for HCW9302 in alopecia areata in the first half of 2026. CEO Hing C. Wong stated, “HCW9302 was selected as the lead product candidate for the Company’s autoimmune program because it has demonstrated relatively high IL-2Rα affinity and sustains serum exposure, which implies it has a strong profile for the treatment of autoimmune disorders.”



<h2>Lingering Going Concern Risks</h2>



Despite pipeline progress, substantial doubt remains about the company’s ability to continue as a going concern without funding. HCW reported cash and equivalents of $1.23 million, down from $1.95 million a year ago.



<h2>Critical Levels to Watch for HCWB Stock</h2>



Even after the pullback, HCWB is still trading well above its short-term trend gauges—about 132.3% above the 20-day SMA (43 cents) and 114.5% above the 50-day SMA (46 cents)—which tells you the recent move has been fast and extended.



At the same time, the longer trend remains pressured, with price still 54.5% below the 200-day SMA ($2.17).



RSI is the cleanest momentum read here: at 82.75, it’s firmly overbought, meaning the stock has been moving up so quickly that it’s vulnerable to sharp snapbacks and profit-taking.



HCWB Price Action: HCW Biologics shares were down 19.09% at $0.98 during premarket trading on Monday, according to Benzinga Pro data.



Image via Shutterstock

HCWB

LABU

IBBQ

SBIO

HCW Biologics (HCWB) reported Q1 EPS of $0.37 and $6.54M in sales, leading to a 262% surge in stock price. However, shares fell 19.09% in premarket trading as investors took profits. Despite pipeline advancements, concerns about the company's financial stability persist, with cash down to $1.23M. HCWB remains significantly above short-term trend gauges but is still 54.5% below its 200-day SMA.

What's Going On With HCW Biologics Stock Monday?